TY - JOUR
T1 - Relapse, cognitive reserve, and their relationship with cognition in first episode schizophrenia
T2 - a 3-year follow-up study
AU - 2EPs group
AU - Sánchez-Torres, Ana M.
AU - Amoretti, Silvia
AU - Enguita-Germán, Mónica
AU - Mezquida, Gisela
AU - Moreno-Izco, Lucía
AU - Panadero-Gómez, Rocío
AU - Rementería, Lide
AU - Toll, Alba
AU - Rodriguez-Jimenez, Roberto
AU - Roldán, Alexandra
AU - Pomarol-Clotet, Edith
AU - Ibáñez, Ángela
AU - Usall, Judith
AU - Contreras, Fernando
AU - Vieta, Eduard
AU - López-Ilundain, Jose M.
AU - Merchán-Naranjo, Jessica
AU - González-Pinto, Ana
AU - Berrocoso, Esther
AU - Bernardo, Miguel
AU - Cuesta, Manuel J.
AU - Forte, María Florencia
AU - González-Díaz, Jairo M.
AU - Parellada, Mara
AU - Abrokwa, Hayford
AU - Segura, María Sans
AU - González, Judit Selma
AU - Zorrilla, Iñaki
AU - González-Ortega, Itxaso
AU - Legido, Teresa
AU - Mané, Anna
AU - Sanchez-Pastor, Luis
AU - Rentero, David
AU - Sarró, Salvador
AU - García-León, Maria Ángeles
AU - Butjosa, Anna
AU - Pardo, Marta
AU - Zarzuela, Amalia
AU - Ribeiro, María
AU - Saiz-Ruiz, Jerónimo
AU - León-Quismondo, Leticia
AU - Hernández, Miguel
AU - de la Cámara, Concepción
AU - Gutiérrez-Fraile, Miguel
AU - González-Blanco, Leticia
N1 - Funding Information:
R. Rodriguez-Jimenez was supported by the Instituto de Salud Carlos III (PI19/00766; Fondo de Investigaciones Sanitarias/FEDER) and of Madrid Regional Government (S2017/BMD-3740)
Funding Information:
A. Ibáñez thanks the support by the Madrid Regional Government (R&D Activities in Biomedicine S2017/BMD3740: AGES-CM 2-CM) and European Union Structural Funds, and the support by CIBERSAM.
Funding Information:
S. Amoretti has been supported by a Sara Borrell (CD20/00177), funded by Instituto de Salud Carlos III (ISCIII) and co-funded by European Social Fund "Investing in your future”.
Funding Information:
We are extremely grateful to all participants. This study is part of a coordinated-multicentre Project, funded by the Ministerio de Economía y Competitividad (PI08/0208; PI08/1026; PI11/02831; PI11/00325; PI14/00612; PI14/1621), Instituto de Salud Carlos III – Fondo Europeo de Desarrollo Regional. Unión Europea. Una manera de hacer Europa, Centro de Investigación Biomédica en Red de salud Mental, CIBERSAM, by the CERCA Programme / Generalitat de Catalunya AND Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement (2017SGR1355). Departament de Salut de la Generalitat de Catalunya, en la convocatoria corresponent a l'any 2017 de concessió de subvencions del Pla Estratègic de Recerca i Innovació en Salut (PERIS) 2016-2020, modalitat Projectes de recerca orientats a l'atenció primària, amb el codi d'expedient SLT006/17/00345. MB is also grateful for the support of the Institut de Neurociències, Universitat de Barcelona. MBe is also grateful for the support of the Institut de Neurociències, Universitat de Barcelona. S. Amoretti has been supported by a Sara Borrell (CD20/00177), funded by Instituto de Salud Carlos III (ISCIII) and co-funded by European Social Fund "Investing in your future”. R. Rodriguez-Jimenez was supported by the Instituto de Salud Carlos III (PI19/00766; Fondo de Investigaciones Sanitarias/FEDER) and of Madrid Regional Government (S2017/BMD-3740), A. Ibáñez thanks the support by the Madrid Regional Government (R&D Activities in Biomedicine S2017/BMD3740: AGES-CM 2-CM) and European Union Structural Funds, and the support by CIBERSAM. This work was supported by: Instituto de Salud Carlos III, the Spanish Ministry of Science, Innovation and Universities, the European Regional Development Fund (ERDF/FEDER) (PI080208, PI08/1026; PI11/02831; PI11/00325, PI14/1621, PI16/02148, PI18/01055, PI14/00612 and PI19/1698); CIBERSAM; the CERCA Program / Generalitat de Catalunya, and Secretaria d'Universitats i Recerca del Departament d'Economia I Coneixement (2017SGR1355) and by the Health Department of the Government of Navarra (grant numbers 87/2014; 17/031 and 41/18).
Funding Information:
This study is part of a coordinated-multicentre Project, funded by the Ministerio de Economía y Competitividad (PI08/0208; PI08/1026; PI11/02831; PI11/00325; PI14/00612; PI14/1621), Instituto de Salud Carlos III – Fondo Europeo de Desarrollo Regional. Unión Europea. Una manera de hacer Europa, Centro de Investigación Biomédica en Red de salud Mental, CIBERSAM, by the CERCA Programme / Generalitat de Catalunya AND Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement (2017SGR1355). Departament de Salut de la Generalitat de Catalunya, en la convocatoria corresponent a l'any 2017 de concessió de subvencions del Pla Estratègic de Recerca i Innovació en Salut (PERIS) 2016-2020, modalitat Projectes de recerca orientats a l'atenció primària, amb el codi d'expedient SLT006/17/00345. MB is also grateful for the support of the Institut de Neurociències, Universitat de Barcelona. MBe is also grateful for the support of the Institut de Neurociències, Universitat de Barcelona.
Funding Information:
This work was supported by: Instituto de Salud Carlos III, the Spanish Ministry of Science, Innovation and Universities, the European Regional Development Fund (ERDF/FEDER) ( PI080208 , PI08/1026 ; PI11/02831 ; PI11/00325 , PI14/1621 , PI16/02148 , PI18/01055 , PI14/00612 and PI19/1698 ); CIBERSAM; the CERCA Program / Generalitat de Catalunya, and Secretaria d'Universitats i Recerca del Departament d'Economia I Coneixement (2017SGR1355) and by the Health Department of the Government of Navarra (grant numbers 87/2014; 17/031 and 41/18).
Publisher Copyright:
© 2022 Elsevier B.V. and ECNP
PY - 2023/2
Y1 - 2023/2
N2 - Schizophrenia is frequently characterized by the presence of multiple relapses. Cognitive impairments are core features of schizophrenia. Cognitive reserve (CR) is the ability of the brain to compensate for damage caused by pathologies such as psychotic illness. As cognition is related to CR, the study of the relationship between relapse, cognition and CR may broaden our understanding of the course of the disease. We aimed to determine whether relapse was associated with cognitive impairment, controlling for the effects of CR. Ninety-nine patients with a remitted first episode of schizophrenia or schizophreniform disorder were administered a set of neuropsychological tests to assess premorbid IQ, attention, processing speed, working memory, verbal and visual memory, executive functions and social cognition. They were followed up for 3 years (n=53) or until they relapsed (n=46). Personal and familial CR was estimated from a principal component analysis of the premorbid information gathered. Linear mixed-effects models were applied to analyse the effect of time and relapse on cognitive function, with CR as covariate. Patients who relapsed and had higher personal CR showed less deterioration in attention, whereas those with higher CR (personal and familial CR) who did not relapse showed better performance in processing speed and visual memory. Taken together, CR seems to ameliorate the negative effects of relapse on attention performance and shows a positive effect on processing speed and visual memory in those patients who did not relapse. Our results add evidence for the protective effect of CR over the course of the illness.
AB - Schizophrenia is frequently characterized by the presence of multiple relapses. Cognitive impairments are core features of schizophrenia. Cognitive reserve (CR) is the ability of the brain to compensate for damage caused by pathologies such as psychotic illness. As cognition is related to CR, the study of the relationship between relapse, cognition and CR may broaden our understanding of the course of the disease. We aimed to determine whether relapse was associated with cognitive impairment, controlling for the effects of CR. Ninety-nine patients with a remitted first episode of schizophrenia or schizophreniform disorder were administered a set of neuropsychological tests to assess premorbid IQ, attention, processing speed, working memory, verbal and visual memory, executive functions and social cognition. They were followed up for 3 years (n=53) or until they relapsed (n=46). Personal and familial CR was estimated from a principal component analysis of the premorbid information gathered. Linear mixed-effects models were applied to analyse the effect of time and relapse on cognitive function, with CR as covariate. Patients who relapsed and had higher personal CR showed less deterioration in attention, whereas those with higher CR (personal and familial CR) who did not relapse showed better performance in processing speed and visual memory. Taken together, CR seems to ameliorate the negative effects of relapse on attention performance and shows a positive effect on processing speed and visual memory in those patients who did not relapse. Our results add evidence for the protective effect of CR over the course of the illness.
UR - http://www.scopus.com/inward/record.url?scp=85146986467&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85146986467&partnerID=8YFLogxK
U2 - 10.1016/j.euroneuro.2022.11.011
DO - 10.1016/j.euroneuro.2022.11.011
M3 - Research Article
C2 - 36495858
AN - SCOPUS:85146986467
SN - 0924-977X
VL - 67
SP - 53
EP - 65
JO - European Neuropsychopharmacology
JF - European Neuropsychopharmacology
ER -